首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations
【2h】

Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations

机译:杀伤时间和突变预防浓度评估磷霉素-妥布霉素组合对铜绿假单胞菌的抗菌活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The antibacterial activity of fosfomycin-tobramycin combination was studied by time-kill assay in eight Pseudomonas aeruginosa clinical isolates belonging to the fosfomycin wild-type population (MIC = 64 μg/ml) but with different tobramycin susceptibilities (MIC range, 1 to 64 μg/ml). The mutant prevention concentration (MPC) and mutant selection window (MSW) were determined in five of these strains (tobramycin MIC range, 1 to 64 μg/ml) in aerobic and anaerobic conditions simulating environments that are present in biofilm-mediated infections. Fosfomycin-tobramycin was synergistic and bactericidal for the isolates with mutations in the mexZ repressor gene, with a tobramycin MIC of 4 μg/ml. This effect was not observed in strains displaying tobramycin MICs of 1 to 2 μg/ml due to the strong bactericidal effect of tobramycin alone. Fosfomycin presented higher MPC values (range, 2,048 to >2,048 μg/ml) in aerobic and anaerobic conditions than did tobramycin (range, 16 to 256 μg/ml). Interestingly, the association rendered narrow or even null MSWs in the two conditions. However, for isolates with high-level tobramycin resistance that harbored aminoglycoside nucleotidyltransferases, time-kill assays showed no synergy, with wide MSWs in the two environments. glpT gene mutations responsible for fosfomycin resistance in P. aeruginosa were determined in fosfomycin-susceptible wild-type strains and mutant derivatives recovered from MPC studies. All mutant derivatives had changes in the GlpT amino acid sequence, which resulted in a truncated permease responsible for fosfomycin resistance. These results suggest that fosfomycin-tobramycin can be an alternative for infections due to P. aeruginosa since it has demonstrated synergistic and bactericidal activity in susceptible isolates and those with low-level tobramycin resistance. It also prevents the emergence of resistant mutants in either aerobic or anaerobic environments.
机译:通过时间杀灭试验研究了磷霉素-妥布霉素组合的抗菌活性,该菌株在八个属于磷霉素野生型种群(MIC = 64μg/ ml)但对妥布霉素敏感度不同(MIC范围为1至64μg)的铜绿假单胞菌临床分离株中/ ml)。在模拟生物膜介导的感染存在的有氧和无氧条件下,在其中五个菌株(妥布霉素MIC范围为1至64μg/ ml)中确定了突变体预防浓度(MPC)和突变体选择窗口(MSW)。磷霉素-妥布霉素对带有mexZ阻遏基因突变的分离株具有协同作用和杀菌作用,妥布霉素MIC为4μg/ ml。由于单独的妥布霉素具有很强的杀菌作用,因此在表现出1至2μg/ ml妥布霉素MIC的菌株中未观察到这种效果。磷霉素在有氧和厌氧条件下的MPC值(范围从2,048至> 2,048μg/ ml)高于妥布霉素(范围在16至256μg/ ml)。有趣的是,在两种情况下,该关联使MSW缩小甚至为空。但是,对于具有高水平对妥布霉素耐药性且带有氨基糖苷核苷酸转移酶的分离株,时间杀灭试验显示没有协同作用,在两种环境中具有广泛的MSW。在对磷霉素敏感的野生型菌株中确定了负责铜绿假单胞菌对磷霉素耐药的glpT基因突变,并从MPC研究中回收了突变体衍生物。所有突变体衍生物的GlpT氨基酸序列均发生变化,导致截短的渗透酶与磷霉素耐药有关。这些结果表明,磷霉素-妥布霉素可以替代铜绿假单胞菌引起的感染,因为它在易感菌株和对妥布霉素耐药性较低的菌株中显示出协同和杀菌活性。它也防止在有氧或厌氧环境中出现抗性突变体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号